The aim of this study was to determine the effect of colloidal bismuth subcitrate (De Nol) on symptoms and gastric histology in patients with non-ulcer dyspepsia. 
asymptomatic (eight of 11 v three of 12, p<005); their gastritis was more likely to resolve (five of 10 v 0 of 12, p<0025) and their gastric biopsies more likely to become negative for Helicobacter like organisms (eight of nine v 0 of 12, p<0-001) when compared with patients taking placebo. In contrast, patients who did not have gastritis in their index biopsies (n=28) fared similarly whether they received colloidal bismuth subcitrate or placebo. Our results indicate that the administration of colloidal bismuth subcitrate benefited non-ulcer dyspepsia patients with gastritis but had no effect on those without.
Therapeutic trials on non-ulcer dyspepsia have yielded conflicting results to date. This is in part a problem of definition. Non-ulcer Patients with non-ulcer dyspepsia fall into two groups depending on the presence or absence of histological gastritis. We have shown that these two groups differ in their response to treatment with colloidal bismuth subcitrate. This may explain the conflicting results of previous treatment trials in non-ulcer dyspepsia. Our demonstration that the majority of patients reported improvement of symptoms regardless of therapy emphasises the need for a placebo group in therapeutic trials in non-ulcer dyspepsia. Our finding that symptoms paralleled changes in gastric histology and the occurrence of Helicobacter like organisms when histological gastritis was present suggests that the gastritis may be the cause of symptoms. In patients who did not have gastritis, the cause of symptoms remains unclear.
As our patients were not stratified at entry into the trial for the presence or absence of gastritis, the present findings therefore should ideally be confirmed by a further trial in which patients are stratified for gastritis. Our results are in agreement with those of Rokkas et al,20 however, and suggest that patients with non-ulcer dyspepsia and histological gastritis benefit from therapy with colloidal bismuth subcitrate. 
